Outcomes of tafasitamab and lenalidomide in large B-cell lymphoma based on prior CD19-directed CAR T exposure.
Saved in:
| Title: | Outcomes of tafasitamab and lenalidomide in large B-cell lymphoma based on prior CD19-directed CAR T exposure. |
|---|---|
| Authors: | Merrill MH; Department of Medicine University of California, San Francisco San Francisco California United States., Redd RA; Department of Medical Oncology Dana-Farber Cancer Institute Boston Massachusetts United States., Lambert N; Department of Medicine Baylor College of Medicine Houston Texas United States., Caimi PF; Department of Hematology and Medical Oncology, Taussig Cancer Institute Cleveland Clinic Foundation Cleveland Ohio United States., Pullarkat P; Division of Hematology-Oncology Massachusetts General Hospital Boston Massachusetts United States., Godby RC; Hematology Division Mayo Clinic Rochester Minnesota United States., Bond DA; Division of Hematology, The James Cancer Hospital and Solove Research Institute The Ohio State University Columbus Ohio United States., Wehmeyer GT; Department of Medicine, Meyer Cancer Center Weill Cornell Medicine and New York Presbyterian Hospital New York New York United States., Romancik J; Department of Hematology and Medical Oncology Winship Cancer Institute at Emory University Atlanta Georgia United States., Amoozgar B; Department of Medicine Washington University School of Medicine St. Louis Missouri United States., Leslie L; Lymphoma Division, John Theurer Cancer Center Hackensack Meridian Health Hackensack New Jersey United States., Nastoupil LJ; Department of Lymphoma and Myeloma M.D. Anderson Cancer Center Houston Texas United States., Crombie JL; Department of Medical Oncology Dana-Farber Cancer Institute Boston Massachusetts United States., Abramson JS; Division of Hematology-Oncology Massachusetts General Hospital Boston Massachusetts United States., Khurana A; Hematology Division Mayo Clinic Rochester Minnesota United States., Nowakowski GS; Hematology Division Mayo Clinic Rochester Minnesota United States., Maddocks K; Division of Hematology, The James Cancer Hospital and Solove Research Institute The Ohio State University Columbus Ohio United States., Rutherford SC; Department of Medicine, Meyer Cancer Center Weill Cornell Medicine and New York Presbyterian Hospital New York New York United States., Kahl B; Department of Medicine Washington University School of Medicine St. Louis Missouri United States., Okwali M; Lymphoma Service, Division of Hematologic Malignancies Memorial Sloan Kettering Cancer Center New York New York United States., Buege MJ; Department of Pharmacy Practice University of Illinois Chicago College of Pharmacy Chicago Illinois United States., Batlevi CL; Genentech Inc. South San Francisco California United States., Armand P; Department of Medical Oncology Dana-Farber Cancer Institute Boston Massachusetts United States., Salles G; Lymphoma Service, Division of Hematologic Malignancies Memorial Sloan Kettering Cancer Center New York New York United States.; Department of Medicine Weill Cornell Medical College New York New York United States., Qualls DA; Department of Medical Oncology Dana-Farber Cancer Institute Boston Massachusetts United States. |
| Source: | HemaSphere [Hemasphere] 2025 Nov 18; Vol. 9 (11), pp. e70253. Date of Electronic Publication: 2025 Nov 18 (Print Publication: 2025). |
| Publication Type: | Letter |
| Journal Info: | Publisher: Wiley Country of Publication: United States NLM ID: 101740619 Publication Model: eCollection Cited Medium: Internet ISSN: 2572-9241 (Electronic) Linking ISSN: 25729241 NLM ISO Abbreviation: Hemasphere Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2572-9241 |
|---|---|
| DOI: | 10.1002/hem3.70253 |
